Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kirros: Atezolizumab +/- Bevacizumab in Advanced Hepatocellular Carcinoma with Child-Pugh B7/B8 Cirrhosis
NCT06096779Phase 2Active, not recruiting
- Sponsor
- Genentech
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of atezolizumab in hepatocellular carcinoma (HCC), sponsored by Genentech. Started Jul 2024; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06096779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06096779.